To: Anthony@Pacific who wrote (49706 ) 1/13/2000 3:36:00 PM From: Anthony@Pacific Read Replies (1) | Respond to of 122087
SNRS<--changes approval request in such a way that it couldnt get turned down.now watch the tsock tank like a brick... This is thge best news ,,now ther eis no more FDA crap to prevent the stock from falling all the way to zero ...when ther is no market for such a pathetic and minscule mkt. This time, Sunrise presented data from two years instead of 18 months and changed the approval it sought. Originally, Sunrise asked the Food and Drug Administration to approve the three-second laser procedure for "correcting" mild-to-moder hyperopia, the medical term for farsightedness. The company changed that request to "reducing" mild-to-moderate hyperopia "where the magnitude of correction diminishes over time." The company's rationale: hyperopic patients over age 40 continue to lose vision over time as the eye ages and loses elasticity, making it unable to focus on objects near and far. These bifocal-wearing patients, according to Sunrise, will continue to lose vision with or without a laser procedure. The FDA, which doesn't have to follow the panel's advice, will make final decision on the product and its specific approval. Sunrise's study showed that some patients still needed to wear glasses or contacts after the surgery. Also, the procedure worked better on older patients than it did on younger ones. Sunrise said about 37 million of the nation's 60 million farsighted people fall into the mild-to-moderate range and will therefore be eligible for the procedure. The laser works by sending two separate rings of eight lasers into the eye around the field of vision. This warms the collagen around the cornea, causing it to shrink and change shape.